TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05372328

Intervention type: OTHER
Group type: OTHER
Intervention: Position of arm while taking blood pressure measurement
Description: Each participant will have 4 sets of 3 blood pressure measurements taken. The participants will be randomized to the order in which their arm position changes prior to each set of measurements.

Intervention type: OTHER
Group type: OTHER
Intervention: Position of arm while taking blood pressure measurement
Description: Each participant will have 4 sets of 3 blood pressure measurements taken. The participants will be randomized to the order in which their arm position changes prior to each set of measurements.

Intervention type: OTHER
Group type: OTHER
Intervention: Position of arm while taking blood pressure measurement
Description: Each participant will have 4 sets of 3 blood pressure measurements taken. The participants will be randomized to the order in which their arm position changes prior to each set of measurements.

Intervention type: OTHER
Group type: OTHER
Intervention: Position of arm while taking blood pressure measurement
Description: Each participant will have 4 sets of 3 blood pressure measurements taken. The participants will be randomized to the order in which their arm position changes prior to each set of measurements.

Intervention type: OTHER
Group type: OTHER
Intervention: Position of arm while taking blood pressure measurement
Description: Each participant will have 4 sets of 3 blood pressure measurements taken. The participants will be randomized to the order in which their arm position changes prior to each set of measurements.

Intervention type: OTHER
Group type: OTHER
Intervention: Position of arm while taking blood pressure measurement
Description: Each participant will have 4 sets of 3 blood pressure measurements taken. The participants will be randomized to the order in which their arm position changes prior to each set of measurements.
Study: NCT05300906

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: personalized 2-week mobile wellbeing intervention
Description: For the study, 27 versions of a 2-week mobile wellbeing intervention are created. These versions vary on content (Cognitive Behavioral Therapy, meaning, positive psychology), feedback (text, text with avatar, pre-recorded video) and design (non-gamified, competitively gamified, storyline gamified). At baseline, participants preview all variations and indicate their expected engagement. Participants in the personalized condition will receive the optimal combination of content, feedback and design, based on their baseline engagement scores.~Each version of the intervention consists of a module per day. Each module contains psychoeducation and exercises based on content of the version. Moreover, each module contains pre-specified general feedback and supportive messages.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: non-personalized 2-week mobile wellbeing intervention
Description: For the study, 27 versions of a 2-week mobile wellbeing intervention are created. These versions vary on content (Cognitive Behavioral Therapy, meaning, positive psychology), feedback (text, text with avatar, pre-recorded video) and design (non-gamified, competitively gamified, storyline gamified). At baseline, participants preview all variations and indicate their expected engagement. Participants in the non-personalized condition will receive a random version of the intervention.~Each version of the intervention consists of a module per day. Each module contains psychoeducation and exercises based on content of the version. Moreover, each module contains pre-specified general feedback and supportive messages.
Study: NCT06478537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hetrombopag Olamine
Description: Treatment period: 24-week Hetrombopag (2.5mg/d\~7.5mg/d) treatment.~* Two consecutive visits with PLT\>600 × 10\^9/L: daily dose reduction of 2.5mg; If the lowest dose has been used, extend the dosing interval.~* Two consecutive visits with PLT\<300 × 10\^9/L: increase the daily dose by 2.5mg until the maximum dose is reached.~* Two consecutive visits with PLT\<50 × 10\^9/L: increase the daily dose by 2.5mg until the maximum dose is reached; If PLT is still\<50 × 10\^9/L with7.5mg/d × 28d, the patient will be withdrawn.~Drug discontinuation period：8-week Hetrombopag (2.5mg/d\~7.5mg/d) reduction. Hetrombopag reduces by 2.5mg every 2 weeks, and after reducing to the minimum dose of 2.5mg/d x 2 weeks, it is changed to 2.5mg once every other day (Qod) treatment, with a maximum reduction time of 8 weeks. If the PLT during two consecutive visits is less than 30 × 10\^9/L, the patient will be withdrawn.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin 100mg, qd
Study: NCT05259007

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: propolis solved in lactic acid solvent
Description: propolis given as a dietary supplement which was solved in a lactic acid solvent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin-Clarithromycin-Lansoprazole
Description: H pylori eradication treatment

Intervention type: DRUG
Group type: OTHER
Intervention: Amoxicillin-Clarithromycin-Lansoprazole
Description: H pylori eradication treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amoxicillin-Clarithromycin-Lansoprazole
Description: H pylori eradication treatment

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: IV saline 0.9%
Description: Physiological serum solution is given as a placebo

Intervention type: OTHER
Group type: OTHER
Intervention: Lactic acid
Description: given to determine if the improvement of the symptoms are due to propolis or the solvent
Study: NCT04962009

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Travoprost Evolute® (Travoprost Punctal Plug Delivery System), 166 ug
Description: Each subject will have his/her lower puncta of each eye inserted with a Travoprost Evolute®. Each study subject will be instructed to return to the investigator's office the next day, 7, 28, 60 and 90-days after the insertion of their plugs for follow-up examinations.
Study: NCT05218473

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Prolonged ECG monitoring
Description: Using 14-day continuous electrocardiography patch monitoring to increase the detection rate of paroxysmal atrial fibrillation in acute ischemic stroke patients without known atrial fibrillation.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Conventional procedure group
Description: Using serial 12-lead electrocardiograms once daily for five days or conventional 24-h Holter monitoring to detect new atrial fibrillation
Study: NCT04903249

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core Exercise Promotion Intervention
Description: Participants are instructed to increase weekly time spent exercising to \>90 minutes over 12 weeks. Exercise will be defined as activities that use large muscle groups, increase heart rate and breathing rate, and are performed intentionally for the purpose of exercise (as opposed to physical activities of daily living, e.g., housework). Participants complete a videoconferencing visit with the study team and are given task and safety related information pertaining to exercise for survivors of cancer. Participants engage in exercise-related goal-setting and action planning and are provided activity trackers to monitor their activity levels over the 12-week study period.
Study: NCT05275530

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active FIT Choice
Description: The investigators will send randomized participants a message via MyChart indicating the benefits of CRC screening, along with tailored information about FIT as a screening strategy. At the end of the message, participants will complete a survey asking them to indicate if they would like to be screened for CRC with a FIT, or if they prefer no screening whatsoever. The investigators will then ask follow-up questions to better understand the reason patients made their respective choices.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Colonoscopy Choice
Description: The investigators will send randomized participants a message via MyChart indicating the benefits of CRC screening, along with tailored information about colonoscopy as a screening strategy. At the end of the message, participants will complete a survey asking them to indicate if they would like to be screened for CRC with a colonoscopy, or if they prefer no screening whatsoever. The investigators will then ask follow-up questions to better understand the reason patients made their respective choices.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Dual Choice
Description: The investigators will send randomized participants a message via MyChart indicating the benefits of CRC screening, along with tailored information about FIT Kit and Colonoscopy screening. At the end of the message, participants will complete a survey asking them to indicate if they would like to be screened for CRC with either a FIT or Colonoscopy, or if they prefer no screening whatsoever. The investigators will then ask follow-up questions to better understand the reason patients made their respective choices.
Study: NCT05447754

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined RAGT and TBT
Description: Combined RAGT and TBT: Participants will be treated with Lokomat for 40 minutes, twice a week for 5 weeks, and RAGT with a body weight support system and combined TBT for 40 minutes each session 3 times a week. During RAGT, 30-40% of each participant's body weight will be taken with the body weight support system. In patients without drop foot and knee instability in the sessions after the first session, the body weight will be reduced by 10% and progression will be achieved. The speed of the treadmill will be adjusted between 1.2-2.6 km/h and the maximum speed tolerated by the patient will be reached during the sessions. TBT exercises 3 times a week for 40 minutes (weight transfer to the paretic leg during sitting and standing, weight transfer during sitting and standing with or without an assistive device) will be personalized according to the patient. Progression of exercises will be provided by adding upper extremity and trunk activities in addition to exercises.
Study: NCT05808010

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mononuclear cells
Description: 2 times gastric submucosal injection of mononuclear cells (10\^8) at 1 month interval

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mononuclear cells
Description: 2 times gastric submucosal injection of mononuclear cells (10\^8) at 1 month interval

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Weifuchun+Hydrotalcite/L-Glutamine and Sodium Gualenate Granules
Description: Orally delivered tablets for 7 months. Take it according to the instructions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Weifuchun+Hydrotalcite/L-Glutamine and Sodium Gualenate Granules
Description: Orally delivered tablets for 7 months. Take it according to the instructions.
Study: NCT06221787

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: 1565 nm non-ablative fractional laser combined with normal saline
Description: After 1565 nm non-ablative fractional laser treatment, patients with melasma were smeared with normal saline and to compared with those smeared with exosomes after laser treatment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: microneedles combined with hUCMSC-Exos
Description: the hUCMSC-Exos were applied while rolling a microneedle roller and to compared with those used 1565 nm non-ablative fractional laser or PBASM combined with hUCMSC-Exos.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 1565 nm non-ablative fractional laser combined with hUCMSC-Exos
Description: After 1565 nm non-ablative fractional laser treatment, patients with melasma were smeared with hUCMSC-Exos and to compared with those smeared with normal saline after laser treatment.What's more,compared with those used microneedles or PBASM combined with hUCMSC-Exos.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PBASM combined with hUCMSC-Exos
Description: a plasma named Peninsula Blue Aurora Shumin Master (PBASM) rolling each area for 8-10 min before applying the hUCMSC-Exos in the entire face. And to compared with those used 1565 nm non-ablative fractional laser or microneedles combined with hUCMSC-Exos.
Study: NCT06344260

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: human Neural Stem Cells (hNSC)
Description: The patient is placed on a regular operating room table with or without rigid head fixation. Procedure will be performed whether under general anesthesia or sedation and local anesthesia. Image guidance will be registered using the frameless stereotactic AxiEM system. Image guidance will be used to perform ventricular cannulation with the catheter passed over an electromagnetic-tipped stylet, which is recognized and tracked by the navigation system. The correct placement of the catheter is verified by the egress of CSF. Finally the electromagnetic stylet will be removed and a Rickam reservoir connect to ventricular catheter. Operative time will be about 30 minute. A post-operative CT scan will be obtained in all patients to confirm the catheter position.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: human Neural Stem Cells (hNSC)
Description: The patient is placed on a regular operating room table with or without rigid head fixation. Procedure will be performed whether under general anesthesia or sedation and local anesthesia. Image guidance will be registered using the frameless stereotactic AxiEM system. Image guidance will be used to perform ventricular cannulation with the catheter passed over an electromagnetic-tipped stylet, which is recognized and tracked by the navigation system. The correct placement of the catheter is verified by the egress of CSF. Finally the electromagnetic stylet will be removed and a Rickam reservoir connect to ventricular catheter. Operative time will be about 30 minute. A post-operative CT scan will be obtained in all patients to confirm the catheter position.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Saline (Placebo)
Description: The patient is placed on a regular operating room table with or without rigid head fixation. Procedure will be performed whether under general anesthesia or sedation and local anesthesia. Image guidance will be registered using the frameless stereotactic AxiEM system. Image guidance will be used to perform ventricular cannulation with the catheter passed over an electromagnetic-tipped stylet, which is recognized and tracked by the navigation system. The correct placement of the catheter is verified by the egress of CSF. Finally the electromagnetic stylet will be removed and a Rickam reservoir connect to ventricular catheter. Operative time will be about 30 minute. A post-operative CT scan will be obtained in all patients to confirm the catheter position.
Study: NCT05447754

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: balance exercises
Description: TBT
Study: NCT05879848

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VR
Description: virtual reality scenario synchronized with the uterine contractions
Study: NCT06276725

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Writing Wrongs
Description: A repeated exposure writing practice targeting symptoms resulting from microaggressions experienced by minoritized students at predominantly White institutions.
Study: NCT05822349

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: picograms-enriched label
Description: The intervention care includes usual care (instructions for using each anti-diabetic drug) plus pictograms that show how much medications should be taken at each time of day (morning, noon, evening, and night), how to take them in relation to meals, the purpose of the drug, and the most important non-pharmacologic interventions for diabetic patients (weight loss, exercise, avoiding smoking, blood sugar controlling).
Study: NCT06067945

Intervention type: OTHER
Intervention: microleakage
Description: prevention of microleakage and secondary carries
Study: NCT05339282

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Description: Method of operation~1. Surgery was started under general anesthesia~2. A trocar of 10 mm was placed on the navel, 5 mm under the blade, and a 5 mm trocar was placed on the right upper abdomen.~3. Pneumoperitoneum was performed using CO2 gas in the abdominal cavity.~4. Dissection started from Calot's triangle, and the operation was performed by retrograde cholecystectomy.~5. The excised gallbladder was placed in a laparoscopic pocket and extracted through the umbilicus.~6. The trocar was removed, and the skin was sutured~On the 1st day after surgery, hematology, blood chemistry, urine, blood clotting, and chest x-rays were performed. (Inspection and treatment were performed according to the current clinical pathway of gallbladder surgery)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Description: Method of operation~1. Surgery was started under general anesthesia~2. A trocar of 10 mm was placed on the navel, 5 mm under the blade, and a 5 mm trocar was placed on the right upper abdomen.~3. Pneumoperitoneum was performed using CO2 gas in the abdominal cavity.~4. Dissection started from Calot's triangle, and the operation was performed by retrograde cholecystectomy.~5. The excised gallbladder was placed in a laparoscopic pocket and extracted through the umbilicus.~6. The trocar was removed, and the skin was sutured~On the 1st day after surgery, hematology, blood chemistry, urine, blood clotting, and chest x-rays were performed. (Inspection and treatment were performed according to the current clinical pathway of gallbladder surgery)
Study: NCT05098509

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RAD011
Description: Cannabidiol Oral Solution (containing synthetic cannabidiol)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RAD011
Description: Cannabidiol Oral Solution (containing synthetic cannabidiol)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RAD011
Description: Cannabidiol Oral Solution (containing synthetic cannabidiol)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo for RAD011
Study: NCT06347939

Intervention type: DIAGNOSTIC_TEST
Intervention: Mediastinal lymph nodes cryobiopsies
Description: EBUS Mediastinal lymph nodes cryobiopsies
Study: NCT06054256

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group CBT-I
Description: The group-based intervention will consist of 6 weekly sessions (90-min, 5-8 pregnant women in each group). The treatment components aim to address the behavioural, cognitive and physiological factors perpetuating insomnia with the followings: psycho-education about sleep and sleep hygiene (e.g., psychoeducation about sleep during pregnancy and normal development and patterns of infant sleep, psychoeducation on ways of improving infant sleep, strategies to limit the development of unwanted sleep associations, etc.), stimulus control, sleep restriction, relaxation training, structured worry time, cognitive restructuring (targeting sleep-related dysfunctional cognitions), and relapse prevention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App-based CBT-I
Description: The smartphone app-based intervention will consist of 6 weekly sessions. The app-based intervention will involve a self-paced, fully automated digital programme with interactive components. The structure of the app involves six sequential modules (comparable to the six treatment sessions delivered in groups) with different elements to engage the users, such as animated videos, case vignettes, narration, quizzes, and homework assignment. Each module will be unlocked and released to the participants every week after the previous module has been completed. Personalised feedback will be provided by the app following the completion of sleep diary each week. Automated messages will be sent to the participants regularly via phone to remind them of implementing learned strategies after each module, as well as timely completing the treatment modules and sleep diaries.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Health related psychoeducation
Description: The control group will receive 6 sessions of group-based health-related psychoeducation, a format that has been adopted in the previous research, in order to provide the credibility of the intervention to the participants, and to control for the potential effects of attention and nonspecific components.
Study: NCT05831254

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health education:Interactive group training
Description: 1. To introduce e-pulse software, which is a personal health record system, to show its use, to provide training materials such as video-brochures about e-pulse. This program will be done as interactive group training~2. Six modular interactive group training, each of which includes the steps of the European Health Literacy Scale of 90 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health education: Individually training
Description: To introduce e-pulse software, which is a personal health record system, to provide training materials such as video-brochures about e-pulse. This education will be done individually.
Study: NCT06530134

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Driving situation and video feedback
Description: At the end of the driving situation, 35 patients will be asked to express themselves and analyze 4 driving situations resulting from the course of the driving situation using video feedback.

Intervention type: OTHER
Group type: OTHER
Intervention: Driving situation and usual recommendations (without video feedback)
Description: At the end of the driving situation, 35 patients will be asked to express themselves and analyze 4 driving situations resulting from the course of the driving situation without video feedback, according to the usual recommendations.~Comparison of responses to all questionnaires and interview grids sent before and after driving, to patients and professionals will determine whether video feedback promotes awareness of the difficulties of driving post-stroke patients.
Study: NCT06422637

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Liquid Biopsy Early Screening
Description: An early screening model for lung cancer aids in identifying individuals with early-stage lung cancer. Those with positive indications of lung cancer will subsequently undergo confirmatory clinical assessments using Low-Dose Computed Tomography (LDCT) in sequence. Ultimately, a definitive diagnosis of lung cancer is established through surgical and pathological examination.